Joy Bauch

Medicine · Health Sciences

21h-index2.7kcitations47works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Peptidase Inhibition and Analysis(10), Synthesis and biological activity(9), Click Chemistry and Applications(9), Cancer therapeutics and mechanisms(9), HER2/EGFR in Cancer Research(7)

Publications47 total

Supplementary Fig. S3 from ABT-263 and rapamycin act cooperatively to kill lymphoma cells <i>in vitro</i> and <i>in vivo</i>
2023Open Access
Supplementary Fig. S1 from ABT-263 and rapamycin act cooperatively to kill lymphoma cells <i>in vitro</i> and <i>in vivo</i>
2023Open Access
Data from ABT-263 and rapamycin act cooperatively to kill lymphoma cells <i>in vitro</i> and <i>in vivo</i>
2023Open Access
Supplementary Fig. S2 from ABT-263 and rapamycin act cooperatively to kill lymphoma cells <i>in vitro</i> and <i>in vivo</i>
2023Open Access
Supplementary Fig. S3 from ABT-263 and rapamycin act cooperatively to kill lymphoma cells <i>in vitro</i> and <i>in vivo</i>
2023Open Access
Data from ABT-263 and rapamycin act cooperatively to kill lymphoma cells <i>in vitro</i> and <i>in vivo</i>
2023Open Access
Supplementary Fig. S1 from ABT-263 and rapamycin act cooperatively to kill lymphoma cells <i>in vitro</i> and <i>in vivo</i>
2023Open Access
Supplementary Fig. S2 from ABT-263 and rapamycin act cooperatively to kill lymphoma cells <i>in vitro</i> and <i>in vivo</i>
2023Open Access
Supplementary Table 1 from A Small-Molecule Inhibitor of Bcl-X<sub>L</sub> Potentiates the Activity of Cytotoxic Drugs <i>In vitro</i> and <i>In vivo</i>
2023Open Access
Data from A Small-Molecule Inhibitor of Bcl-X<sub>L</sub> Potentiates the Activity of Cytotoxic Drugs <i>In vitro</i> and <i>In vivo</i>
2023Open Access
Data from A Small-Molecule Inhibitor of Bcl-X<sub>L</sub> Potentiates the Activity of Cytotoxic Drugs <i>In vitro</i> and <i>In vivo</i>
2023Open Access
Supplementary Table 1 from A Small-Molecule Inhibitor of Bcl-X<sub>L</sub> Potentiates the Activity of Cytotoxic Drugs <i>In vitro</i> and <i>In vivo</i>
2023Open Access
Endothelin receptor antagonist has limited access to the fetal compartment during chronic maternal administration late in pregnancy
Life Sciences·2012· 15 citedOpen Access
Evaluation of the Oral Antimitotic Agent (ABT-751) in Dogs with Lymphoma
Journal of Veterinary Internal Medicine·2012· 5 cited
Tumour‐selective antivascular effects of the novel anti‐mitotic compound A‐318315: An<i>in vivo</i>rat regional haemodynamic study
Clinical and Experimental Pharmacology and Physiology·2010· 3 cited
Plasma and cerebrospinal fluid pharmacokinetics of ABT-888 after oral administration in non-human primates
Cancer Chemotherapy and Pharmacology·2009· 34 citedOpen Access
Use of the H<sub>3</sub>receptor antagonist radioligand [<sup>3</sup>H]‐A‐349821 to reveal<i>in vivo</i>receptor occupancy of cognition enhancing H<sub>3</sub>receptor antagonists
British Journal of Pharmacology·2009· 18 citedOpen Access
Discovery of an Orally Bioavailable Small Molecule Inhibitor of Prosurvival B-Cell Lymphoma 2 Proteins
Journal of Medicinal Chemistry·2008· 291 citedOpen Access
ABT-263 and rapamycin act cooperatively to kill lymphoma cells <i>in vitro</i> and <i>in vivo</i>
Molecular Cancer Therapeutics·2008· 73 cited
Activity of the Bcl-2 Family Inhibitor ABT-263 in a Panel of Small Cell Lung Cancer Xenograft Models
Clinical Cancer Research·2008· 209 cited
page 1 of 3Next →

Frequent Co-authors

Saul H. Rosenberg(32), Kennan C. Marsh(28), David J. Frost(21), Steven W. Elmore(19), Stephen W. Fesik(18), Anatol Oleksijew(17), Alex R. Shoemaker(16), Baole Wang(15), Christin Tse(12), Michael J. Mitten(12), Marion Refici(11), Hing L. Sham(11), Stephen K. Tahir(10), Haichao Zhang(10), Scott Ackler(10), Vincent S. Stoll(9), Sally Schlessinger(9), Sanjay R. Chemburkar(9), Tilman Oltersdorf(8), Kelly Foster(8)